1 hr ago
The Washington Post
Benefit of Cancer Probe With Less Erection Risk Examined by FDA
A device used in Europe to treat prostate cancer with lower rates of erectile dysfunction raised concerns from U.S. regulators over data the company says shows it prevents the disease's return.
EDAP Completes FDA Inspection of Manufacturing Site
EDAP TMS SA , the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration concluded its routine inspection of EDAP's manufacturing site with no findings nor issuance of Form 483 observations.
EDAP Closes $9.3 Million Registered Direct Offering
The Company intends to use a portion of the net proceeds to advance preparatory activities in connection with the Ablatherm-HIFU PMA process and the upcoming .
EDAP to Raise $9.3 Million in Registered Direct Offering
The securities described above are being offered pursuant to a shelf registration statement , which was declared effective by the .